Breaking News Instant updates and real-time market news.

ETTX

Entasis Therapeutics

$6.23

0.04 (0.65%)

08:21
06/27/19
06/27
08:21
06/27/19
08:21

Entasis Therapeutics announces new results on antimicrobial programs

Entasis Therapeutics Holdings announced multiple presentations of its innovative programs including sulbactam-durlobactam, zoliflodacin and ETX0282CPDP, during the American Society for Microbiology Microbe Conference 2019. Durlobactam has been approved as the international nonproprietary name for ETX2514. During the conference, Ruben Tommasi, PhD, Chief Scientific Officer at Entasis, provided an overview of the Company's pipeline, underscoring the broad antibacterial activity of sulbactam-durlobactam against Acinetobacter through inhibition of Class A, C and D beta-lactamases and the potential utility of zoliflodacin as a novel single-dose oral treatment for gonorrhea. Dr. Tommasi also discussed ETX0282CPDP's potential as a best-in-class oral agent with potent microbiological activity against multi-drug resistant Enterobacteriaceae, and the Company's novel non-beta-lactam PBP inhibitor program designed to address serious Gram-negative infections. John O'Donnell, Senior Director of Drug Metabolism and Pharmacokinetics at Entasis, spoke and provided a poster presentation on pharmacokinetics, pharmacodynamics and dose projections for sulbactam-durlobactam. These results formed the basis of the dosing regimen tested in the Phase 2 and ongoing ATTACK Phase 3 clinical trial. John Mueller, PhD, Chief Development Officer of Entasis, reviewed novel therapies targeting drug-resistant gonorrhea, including Entasis' first-in-class antibiotic zoliflodacin, which represents the only known novel treatment in late-stage development against this pathogen. In addition, multiple poster presentations demonstrated the potent antibacterial activity of sulbactam-durlobactam against recent geographically diverse, multidrug-resistant Acinetobacter isolates, and the potent antibacterial activity of ETX0282CPDP against contemporary multidrug-resistant Enterobacteriaceae isolates.

ETTX Entasis Therapeutics
$6.23

0.04 (0.65%)

10/22/18
FBCO
10/22/18
INITIATION
Target $18
FBCO
Outperform
Entasis Therapeutics initiated with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster started Entasis Therapeutics with an Outperform rating and $18 price target. The analyst notes that Entasis has two Phase 3-ready assets, with ETX2514 being the key value driver for the stock. ETX2514 is being developed to address difficult-to-treat Acinetobacter infections, and has shown promising preclinical efficacy, good tissue distribution, and a clean safety profile to date, he contends. Auster is modeling a 45% probability of success to this program, but projects a potential $400M global peak opportunity by 2033 in this setting.
10/24/18
RHCO
10/24/18
INITIATION
Target $20
RHCO
Buy
Entasis Therapeutics initiated with a Buy at SunTrust
SunTrust analyst Edward Nash initiated Entasis Therapeutics with a Buy rating and a price target of $20, saying the company is "uniquely positioned by targeting bacterial infections where few therapeutic options exist" while also "increasing rates of multi-drug resistance". The analyst notes that Entasis' lead antibiotic "has the potential to grab significant market share as the drug will target well-defined patient populations with limited treatment options" given up to 200K of registered Acinetobacter infections in the U.S. and the E.U.
10/24/18
10/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at JMP Securities. 2. Comcast (CMCSA) resumed with a Buy at Deutsche Bank, reinstated with a Buy at Citi, and assumed with a Neutral at Guggenheim. 3. 2U (TWOU) initiated with a Buy at Needham. 4. Corbus Pharmaceuticals (CRBP) initiated with a Buy at B. Riley FBR. 5. Entasis Therapeutics (ETTX) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/08/18
FBCO
11/08/18
NO CHANGE
Target $18
FBCO
Outperform
NEJM article on Entasis' Zoli increases awareness, validates novelty, says Credit Suisse
Credit Suisse analyst Martin Auster notes that Entasis Therapeutics' Phase 2 trial produced positive results, per protocol, demonstrating Zoliflodacin's potential impact on the growing antibiotic-resistance epidemic. As characterized by an NEJM editorial, N. gonorrhea can be a devastating infection if untreated, so the emergence of antibiotic-resistant strands is rather troublesome, he contends, adding that the article describes Zoli's single-dose regimen as "promising," owing to the challenges that occur when following up with patients. Auster continues to believe that an oral, single dose alternative to the SoC will add visibility and credibility to the company's novel pipeline. The analyst reiterates an Outperform rating and $18 price target on the shares.

TODAY'S FREE FLY STORIES

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$123.46

-0.2 (-0.16%)

11:20
07/18/19
07/18
11:20
07/18/19
11:20
Options
Put buyer in Investment Grade Corporate Bond ETF »

Put buyer in Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FULC

Fulcrum Therapeutics

$0.00

(0.00%)

11:18
07/18/19
07/18
11:18
07/18/19
11:18
Syndicate
Breaking Syndicate news story on Fulcrum Therapeutics »

Fulcrum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

11:17
07/18/19
07/18
11:17
07/18/19
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

11:16
07/18/19
07/18
11:16
07/18/19
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
07/18/19
07/18
11:15
07/18/19
11:15
General news
Treasury announced a $113 B 3-pronged package of shorter coupons »

Treasury announced a $113…

11:15
07/18/19
07/18
11:15
07/18/19
11:15
General news
Breaking General news story  »

8-Week Bill Auction to be…

11:15
07/18/19
07/18
11:15
07/18/19
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

XOP

SPDR Oil Exploration and Production Fund

$24.46

-0.15 (-0.61%)

11:10
07/18/19
07/18
11:10
07/18/19
11:10
Options
Size put rolldown in Oil and Gas Exploration ETF »

Size put rolldown in Oil…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
5-Yr Note Announcement CUSIP Number data reported »

5-Yr Note Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
5-Yr Note Announcement Offering Amount data reported »

5-Yr Note Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
7-Yr Note Announcement CUSIP Number data reported »

7-Yr Note Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
2-Yr Note Announcement CUSIP Number data reported »

2-Yr Note Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
7-Yr Note Announcement Offering Amount data reported »

7-Yr Note Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
6-Month Bill Announcement Offering Amount data reported »

6-Month Bill Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
2-Yr Note Announcement Offering Amount data reported »

2-Yr Note Announcement…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
2-Yr FRN Note Announcement CUSIP Number data reported »

2-Yr FRN Note…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
FX Action: USD-CAD »

FX Action: USD-CAD is on…

11:10
07/18/19
07/18
11:10
07/18/19
11:10
General news
2-Yr FRN Note Announcement Offering Amount data reported »

2-Yr FRN Note…

11:09
07/18/19
07/18
11:09
07/18/19
11:09
General news
3-Month Bill Announcement Offering Amount data reported »

3-Month Bill Announcement…

YGTY

SSLJ.com

$1.36

0.1 (7.94%)

11:06
07/18/19
07/18
11:06
07/18/19
11:06
Hot Stocks
SSLJ.com announces resignation of auditor »

SSLJ.com Limited…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBPH

Spring Bank Pharmaceuticals

$5.23

0.12 (2.35%)

11:05
07/18/19
07/18
11:05
07/18/19
11:05
Hot Stocks
Spring Bank reports agreement for HBV antisense oligonucleotide compounds »

Spring Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSRM

SSR Mining

$15.23

0.335 (2.25%)

11:05
07/18/19
07/18
11:05
07/18/19
11:05
Options
SSR Mining call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

AMRB

American River

$12.92

(0.00%)

11:03
07/18/19
07/18
11:03
07/18/19
11:03
Hot Stocks
American River increases quarterly dividend to 7c per share from 5c »

American River Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

FULC

Fulcrum Therapeutics

$0.00

(0.00%)

11:02
07/18/19
07/18
11:02
07/18/19
11:02
Syndicate
Breaking Syndicate news story on Fulcrum Therapeutics »

Fulcrum Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

XRX

Xerox

$34.82

-0.04 (-0.11%)

11:02
07/18/19
07/18
11:02
07/18/19
11:02
Hot Stocks
Xerox wins multiyear intelligent workplace services contract »

Xero has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.